What percentage of patients have statin muscle intolerance based on the criteria you and your colleagues have developed? Why is there a disconnect between the prevalence of statin muscle intolerance vs the results reported in major trials?

What percentage of patients have statin muscle intolerance based on the criteria you and your colleagues have developed? Why is there a disconnect between the prevalence of statin muscle intolerance vs the results reported in major trials?

What percentage of patients have statin muscle intolerance based on the criteria you and your colleagues have developed? Why is there a disconnect between the prevalence of statin muscle intolerance vs the results reported in major trials?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY